earnings
confidence high
sentiment positive
materiality 0.70
Harvard Bioscience preliminary Q4 revenue $23.7M, adj EBITDA $3.8M, 27% YoY growth
HARVARD BIOSCIENCE INC
2025-FY EPS
reported -$1.28
vs consensus $0.36
▼ miss
(-458.5%)
- Preliminary Q4 revenue $23.7M, above guidance midpoint; gross margin 60% at high end of 58-60% range.
- Adjusted EBITDA $3.8M, up 27% YoY, driven by cost reductions and expense management.
- 2026 outlook: year-over-year revenue growth and mid-to high-single-digit adjusted EBITDA growth.
- Strategy focuses on translational science tools, consumables expansion (55% recurring revenue), and operational excellence.
- Full Q4 and FY2025 results to be released March 12, 2026.